FDA Extends Tinlarebant Review to May 2027

Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock;…

Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock;…